Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

The Growing Popularity of DIY Prescription Drugs

by September 17, 2024
September 17, 2024
The Growing Popularity of DIY Prescription Drugs

Jeffrey A. Singer

Axios reported on September 16 that a growing number of people are turning to do-it-yourself versions of prescription drugs, often sharing advice in online chat communities and listservs. Among the more popular DIY drugs are GLP-1s, such as semaglutide and tirzepatide, which help people lose weight—and may even help people reduce alcohol, tobacco, and recreational drug consumption—by directly working on the brain to reduce craving and increase satiety.

The Axios reporter stated that the “knee-jerk reaction” of medical professionals is to deride the phenomenon. However, she interviewed Anne Wexler, an assistant professor of medical ethics and health policy at the University of Pennsylvania Perelman School of Medicine, who empathized with the do-it-yourselfers. Wexler empathizes with patients who grow desperate and “willing to do anything to alleviate suffering for themself or a loved one,” and told the reporter that DIY medicine tends to “pop up where we see access barriers to treatment.”

As Michael F. Cannon and I write in Drug Reformation: End Government’s Power to Require Prescriptions, the Food and Drug Administration has a monopoly on determining what drugs autonomous adults are allowed to buy over-the-counter and what drugs they cannot purchase without first receiving a permission slip (aka “prescription”) from a government-licensed gatekeeper (aka “licensed health care practitioner”). This infringes on adults’ fundamental right to self-medicate. The FDA’s monopoly on the drug approval process also delays or blocks patients’ access to many drugs that patients may access in other developed countries, a phenomenon called “drug lag.”

As I wrote last month, while the FDA has not removed barriers to patients obtaining GLP-1s without a prescription, a recent study found people are already effectively buying GLP‑1 over the counter in a grey market. Last spring, Cato adjunct scholar Charles Silver joined Michael Cannon and me in calling for the FDA to reclassify GLP-1s as over-the-counter.

As the Axios reporter Tina Reed wrote:

The DIY movement taps into a deeply held sentiment about an individuals’ autonomy when it come to accessing particular health interventions without the gatekeeping of the Food and Drug Administration or the sometimes untenable costs of certain drugs or therapies.

Of course, making or buying DIY drugs can be as risky as obtaining any other drug in an underground market. It’s the government’s monopoly on the drug approval process that fuels this underground market. It would be much safer to purchase legally manufactured drugs from retailers where the market and the tort system hold producers and retailers accountable for harmful side effects or defective products. Until lawmakers undertake reforms like those outlined in Drug Reformation, the DYI drug use phenomenon is likely to become more common.

0
FacebookTwitterGoogle +Pinterest
previous post
Watchdog group launches legal probe into NASA emails over ‘Space Czar’ Harris as astronauts linger in orbit
next post
70% Say Founders Would Disagree with How We Currently Follow the Constitution

You may also like

Joint Economic Committee Report Sounds the Alarm on...

March 25, 2025

First Impressions of the AI Order’s Impact on...

November 3, 2023

The Hidden Cost of Your Federally Subsidized Rum:...

November 14, 2023

DOL Must Update Its Shortage Occupation List to...

April 30, 2024

The SEC’s Market Surveillance System Implicates the Fourth...

February 22, 2024

The Court Went Too Far on Presidential Immunity

July 3, 2024

High Costs of Low-Income Housing

December 18, 2023

New Defending Globalization Content: China Shock, Global Capital...

December 12, 2023

Populism and the Future of the Fed: A...

July 29, 2022

New Study Highlights Jones Act Costs to East...

December 12, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Musk jokes about reconsidering stance on Big Beautiful Bill after Schiff’s praise

      June 7, 2025
    • Musk deletes explosive posts about Trump and Epstein files

      June 7, 2025
    • House witness flips script on Dem who ambushed him during hearing with unearthed tweet: ‘Iceberg is ahead’

      June 7, 2025
    • Call with China’s Xi, and Trump-Musk exchange fueled barbs during 20th week in office

      June 7, 2025
    • Trump’s conservative allies warn Congress faces critical ‘test’ with $9.4B spending cut proposal

      June 7, 2025
    • Tech ETFs are Leading Since April, but Another Group is Leading YTD

      June 7, 2025

    Categories

    • Business (8,152)
    • Investing (2,019)
    • Politics (15,567)
    • Stocks (3,136)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved